ADVL1921, PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
What is the goal of the study?
Palbociclib (PD-0332991) is a highly selective, reversible, small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, administered orally. Cyclin D1 and CDK4/6 are downstream of multiple signaling pathways which lead to cellular proliferation. CDKs are important regulatory enzymes that mediate cell cycle control by regulating and promoting transition through the cell cycle. While a number of various CDK enzymes are recognized, in complex organisms the control over cell cycle entry is regulated at the level of CDK4 and CDK6. As cancer represents a process of uncontrolled cell division and proliferation, CDKs represent potential therapeutic targets. Palbociclib (PD-0332991) is being evaluated in combination with Irinotecan and Temozolomide or in combination with Toptecan and Cyclophosphamide
Who can participate in the study?
Please contact the study team listed below to learn more.